Zentalis Pharmaceuticals, Inc. (ZNTL)
NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 3.1100 |
| 開市 | 3.0900 |
| 買盤 | 3.0300 x 600 |
| 賣出價 | 3.0600 x 300 |
| 今日波幅 | 3.0200 - 3.1401 |
| 52 週波幅 | 2.8300 - 21.3400 |
| 成交量 | |
| 平均成交量 | 1,775,171 |
| 市值 | 216.168百萬 |
| Beta 值 (5 年，每月) | 1.70 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.6400 |
| 業績公佈日 | 2024年11月04日 - 2024年11月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 9.90 |
ZacksBiotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
- Zacks
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
BenzingaFDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.’s (NASDAQ:ZNTL) azenosertib, the company’s novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities across the azenosertib development program as quickly as possible. Al
